31 related articles for article (PubMed ID: 2995930)
1. Nabilone in the management of prochlorperazine resistant cancer chemotherapy induced emesis.
Niamatali C; Fallon SD; Egan EL
Ir Med J; 1984 Sep; 77(9):276-7. PubMed ID: 6090342
[No Abstract] [Full Text] [Related]
2. Nabilone and high-dose metoclopramide: anti-emetics for cancer chemotherapy.
Drug Ther Bull; 1984 Feb; 22(3):9-11. PubMed ID: 6321126
[No Abstract] [Full Text] [Related]
3. Synthetic marijuana for nausea and vomiting due to cancer chemotherapy.
Med Lett Drugs Ther; 1985 Nov; 27(701):97-8. PubMed ID: 2999571
[No Abstract] [Full Text] [Related]
4. Levonantradol: a synthetic cannabinoid in the treatment of severe chemotherapy-induced nausea and vomiting resistant to conventional anti-emetic therapy.
Stuart-Harris RC; Mooney CA; Smith IE
Clin Oncol; 1983 Jun; 9(2):143-6. PubMed ID: 6309451
[TBL] [Abstract][Full Text] [Related]
5. Pharmacology. Counteracting side-effects.
Donovan A
Nurs Mirror; 1985 Oct; 161(14):38-9. PubMed ID: 2995930
[No Abstract] [Full Text] [Related]
6. Nabilone (Cesamet) for chemotherapy-induced nausea and vomiting.
Med Lett Drugs Ther; 2006 Dec; 48(1249/1250):103-4. PubMed ID: 17149361
[No Abstract] [Full Text] [Related]
7. [The magic plant as an antiemetic. Cannabinoids for treatment of nausea and vomiting].
Kreutz S
Pharm Unserer Zeit; 2007; 36(5):389-92. PubMed ID: 17722146
[No Abstract] [Full Text] [Related]
8. An overview of ondansetron for chemotherapy-induced nausea and emesis.
San Angel F
J Intraven Nurs; 1993; 16(2):84-9. PubMed ID: 8478782
[TBL] [Abstract][Full Text] [Related]
9. Prevention of chemotherapy-induced nausea and vomiting in patients with cancer.
Aapro MS
Ariz Med; 1981 Nov; 38(11):843-5. PubMed ID: 6274276
[No Abstract] [Full Text] [Related]
10. [Treatment of chemotherapy-induced nausea].
Heikkinen M
Duodecim; 1993; 109(10):913-5. PubMed ID: 8062658
[No Abstract] [Full Text] [Related]
11. Drug insight: New antiemetics in the management of chemotherapy-induced nausea and vomiting.
Oo TH; Hesketh PJ
Nat Clin Pract Oncol; 2005 Apr; 2(4):196-201. PubMed ID: 16264934
[TBL] [Abstract][Full Text] [Related]
12.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
13.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
